ArticleBMJ open ophthalmology2026
Retinal vasculature-derived proteins serve as potential systemic biomarkers for diabetic retinopathy.
Article in BMJ open ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeFibrovascular membrane (FVM), a pathological tissue causing retinal traction, represents an advanced stage of proliferative diabetic retinopathy (PDR). This study aimed to identify novel protein biomarkers associated with retinal microvascular damage leading to FVM formation and to evaluate the diagnostic potential of stratifin (SFN) and hornerin (HRNR) in patients with type 2 diabetes mellitus (T2DM) and diabetic retinopathy (DR).
methodsHuman retinal vasculature from non-diabetic donors and FVM tissues from PDR patients undergoing PPV were analyzed by one-dimensional liquid chromatography-mass spectrometry to identify differentially expressed proteins. Functional enrichment and protein interaction analyses were performed using STRING databases. Selected proteins' messenger RNA expression was quantified by quantitative PCR (qPCR) in peripheral blood mononuclear cells from healthy, T2DM, and DR with nephropathy (DR with DN) patients. Serum levels of SFN and HRNR were measured by ELISA in T2DM, DR, and DR with DN cohorts. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curves.
resultsA total of 44 FVM specific proteins were identified, notably SFN and HRNR linked to retinal angiogenesis. Serum HRNR levels were significantly decreased in DR with DN compared with T2DM, whereas SFN levels were significantly increased in DR versus T2DM. ROC analyses demonstrated acceptable accuracy for differentiating DR stages based on serum SFN and HRNR levels.
conclusionsThis is the first study to identify SFN and HRNR as systemic candidate biomarkers reflecting microvascular alterations in DR. Larger cohort studies are warranted to validate their clinical relevance for early detection and therapeutic targeting of DR.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.